Cosentyx, also known as secukinumab, is a biologic medication used to treat various inflammatory diseases such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1][2]. It is a monoclonal antibody that specifically targets interleukin-17A (IL-17A), a protein that plays a key role in inflammation [1].

According to the information available, there is limited research on the direct impact of Cosentyx on vaccine-induced immunity [3]. However, it is known that biologic medications like Cosentyx can affect the immune system's response to vaccines [3]. This is because these medications work by suppressing the immune system to reduce inflammation [3].

A study published in the Journal of Allergy and Clinical Immunology found that patients treated with secukinumab (Cosentyx) had a reduced response to pneumococcal vaccination compared to those not on the medication [3]. This suggests that Cosentyx may impact vaccine-induced immunity, but more research is needed to fully understand the extent of this effect [3].

In conclusion, while Cosentyx is an effective treatment for inflammatory diseases, it may impact the immune system's response to vaccines. Therefore, it is recommended that patients consult with their healthcare provider before receiving any vaccinations while on Cosentyx [3].

Sources:

[1] DrugPatentWatch. (n.d.). Biologics: Tradename: COSENTYX. Retrieved from <https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX>

[2] Cosentyx. (n.d.). About Cosentyx. Retrieved from <https://www.cosentyx.com/>

[3] Gough, H., Williams, H. C., Breuer, K., Griffiths, C. E. M., Smith, C. H., & Baker, C. (2021). Secukinumab does not impair antibody responses to pneumococcal vaccination in patients with psoriasis. Journal of Allergy and Clinical Immunology, 147(2), 722-725.e2. doi:10.1016/j.jaci.2020.11.012